Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract
Authors:
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1)Cancer, 1997
- Toxicity and Results of MVAC (Methotrexate, Vinblastine, Adriamycin and Cisplatin) Chemotherapy in Advanced Urothelial CarcinomaEuropean Urology, 1997
- Chemotherapy with Methotrexate, Vinblastine, Epirubicin and Carboplatin (Carbo-MVE) in Transitional Cell Urothelial CancerEuropean Urology, 1997
- A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.Journal of Clinical Oncology, 1992
- Cisplatin, Cyclophosphamide and Doxorubicin Chemotherapy for Unresectable Urothelial Tumors: The M. D. Anderson ExperienceJournal of Urology, 1989
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1988
- Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.Journal of Clinical Oncology, 1985
- Cyclophosphamide, Doxorubicin and Cisplatin Chemotherapy for Patients with Locally Advanced Urothelial Tumors with or without Nodal MetastasesJournal of Urology, 1985
- Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1985
- Chemotherapy of Metastatic Bladder CancerCancer, 1980